

# Endoscopic remission in Crohn’s disease trials

	Therapy	Timing of assessment	“Mucosal healing” definition	MH rate (%)	
SONIC	AZA monotherapy	Week 26	Absence of mucosal ulceration	17,0	
	AZA + IFX combo			44,0	
	IFX			30,0	
ACCENT I endoscopic study	IFX scheduled every 8 weeks	Week 54	Absence of mucosal ulceration in previously affected segment	44,0	
	Episodic IFX treatment			18,0	
EXTENT	ADA	Week 12	Absence of mucosal ulceration	27,0	
	PBO			13,0	
	ADA	Week 52		24,0	
	PBO			0,0	
MUSIC	Certolizumab pegol	Week 10	CDEIS <6	37,0	
		Week 54		27,0	
VERSIFY	VDZ	Week 26	SES-CD ≤4	12,0	
		Week 52		18,0	
UNITI endoscopy substudy	UST 90 mg Q8W	Week 44	SES-CD <2	17,0	
	UST 90 mg Q12W			6,0	
	PBO			4,0	
ADVANCE & MOTIVATE	RSZ 600mg	Week 12	SES-CD ≤4 with ulcerated surface subscore 0	21,0	14,0
	RSZ 1200mg			16,0	15,0
	PBO			8,0	4,0
FORTIFY	RSZ 180	Week 52	SES-CD ≤4 with ulcerated surface subscore 0	24,0	
	RSZ 360			31,0	
	PBO			10,0	
U-EXCEL & U-EXCEED	UPA 45 mg	Week 12	SES-CD ≤4	28,9	19,1
	PBO			7,4	2,3
U-ENDURE	UPA 15 mg	Week 52	SES-CD ≤4	19,1	
	UPA 30 mg			23,6	
	PBO			5,5	
VIVID-1	MIRI	Week 12	SES-CD ≤4	10,9	
	PBO			4,0	
GALAXI 1	GUS 100mg	Week 48	SES-CD ≤4	26,0	
	UST			14,0	
GALAXI 2&3	GUS 100mg q8w / GUS 200 q4w	Week 48	SES-CD ≤4	33/ 37	
	UST			25,0	

